

Brian F. Faulkner

A PROFESSIONAL LAW CORPORATION

27127 CALLE ARROYO, SUITE 1923 . SAN JUAN CAPISTRANO, CALIFORNIA 92675
T: 949.240.1361 . F: 949.240.1362 . C: 714.608.2125
E: BRIFFAULK@AOL.COM

September 14, 2024

OTC Markets Group Inc.
300 Vesey Street, 12th Floor
New York, New York 10282

Re: CYduct Diagnostics Inc. (CYDX)

Dear Sir/Madame:

I have been retained by CYduct Diagnostics Inc., a Nevada corporation (“Company”), for the purpose of rendering this letter to OTC Markets Group Inc. (“OTC Markets”) with respect to the information publicly disclosed by the Company and published in the OTC Disclosure & News Service. OTC Markets is entitled to rely on this letter in determining whether the Company has made adequate current information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933, as amended (“Securities Act”).

I hereby represent that I am a U.S. resident. I am licensed to practice law in the State of California and I am permitted to practice before the U.S. Securities and Exchange Commission (“SEC”); I have not been prohibited from practice before them. As such, I am permitted to opine on the federal laws of the United States. I have been retained by the Company for the purpose of rendering this letter and related matters solely for the purpose of reviewing the current information supplied by the Company; as such, I was not involved in the drafting of such current information. I have not received, and do not have any agreement to receive in the future, shares of the Company’s issuer’s stock, in payment for services.

I am not currently, or have in the past five years, been the subject of an investigation, hearing, or proceeding by the SEC, the U.S. Commodity Futures Trading Commission (“CFTC”), the Financial Industry Regulatory Authority (“FINRA”), or any other federal, state, or foreign regulatory agency. I am not currently, or have in the past five years, been suspended or barred from practicing in any state or jurisdiction (and have not been charged in a civil or criminal case).

In connection with rendering this opinion, I have investigated such corporate records and other documents, and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter. In examining the documents, I have assumed the genuineness

of signatures (both manual and conformed), the authenticity of documents submitted as originals, the conformity with originals of all documents furnished as copies and the correctness of facts set forth in such documents (all such sources are believed to be reliable).

I have reviewed the following documents (“Information”) in connection with the preparation of this letter:

<u>Document</u>	<u>Date of Posting on OTC Disclosure & News Service</u>
Amended Annual Disclosure Statement – Year Ended June 30, 2024	September 11, 2024
Annual Disclosure Statement – Year Ended June 30, 2024	September 9, 2024
Quarterly Disclosure Statement – Quarter Ended March 31, 2024	May 1, 2024
Amended Quarterly Disclosure Statement – Quarter Ended December 31, 2023	February 12, 2024
Quarterly Disclosure Statement – Quarter Ended December 31, 2023	February 5, 2024
Quarterly Disclosure Statement – Quarter Ended September 30, 2023	November 13, 2023

Based on the examination and inquiry set forth above, I am of the opinion that Information: (a) constitutes “adequate current public information” concerning the common stock of the Company quoted on the OTC Markets (“Securities”) and the Company itself, and “is available” within the meaning of Rule 144(c)(2) under the Securities Act; (b) includes all of the information that a broker-dealer would be required to obtain from the Company to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934, as amended; (c) complies as to form with the OTC Markets Group’s Pink Basic Disclosure Guidelines, which are located on the Internet at www.otcmarkets.com; and (d) has been posted through the OTC Disclosure & News Service.

The financial statements are not audited and Claus Madsen, the Company’s chief financial officer, was responsible for the preparation of the financial contained in the Information. Mr. Madsen is actively licensed as a certified public accountant in the State of California, and in the past was a senior manager in the audit group at Arthur Andersen. He has worked as a controller and chief financial officer at various companies.

The Company’s transfer agent is Pacific Stock Transfer Company. (“Transfer Agent”). The Transfer Agent is registered with the SEC. I have confirmed the number of outstanding shares as set forth in the Information by reviewing the records of the Company and the Transfer Agent by obtaining a stockholder list from the Transfer Agent.

I met virtually with Dom Gatto, the Company's president and chief executive officer, and sole director of the Company, and Mr. Madsen, for the purpose of: (a) reviewing the Information; and (b) discussing the Information with such management and the sole director.

To my best knowledge, after inquiry of management and the directors of the Company, neither the Company, its officers and directors, any holder of 5% or more of the securities of the Company, nor this counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or states securities laws. Neither the Company, nor its predecessors, is or has ever been a "shell company" as defined in Rule 405 of the Securities Act of 1933, as amended, and Rule 12b-2 of the Securities Exchange Act of 1934, as amended.

This letter is being delivered to OTC Markets for its sole use and benefit and is not to be used, circulated, quoted or otherwise referred to or relied upon for any other purpose without express written consent, except that OTC Markets has full and complete permission and rights to publish this letter through the OTC Disclosure & News Service for viewing by the public and regulators.

It is understood that I express no opinion as to the applicability to or compliance with any state securities laws and regulations. In addition, this letter is given as of the date set forth above and is restricted to the stated facts and circumstances presented to me and described herein, and that any other or different facts and circumstances might require a different letter by me. I assume no, and hereby disclaim any, obligation to update or supplement this letter to reflect any facts or circumstances that may hereafter come to my attention or any changes in laws that may hereafter occur.

Sincerely,

A handwritten signature in black ink, appearing to read "B. Faulkner", with a long horizontal flourish extending to the right.

Brian F. Faulkner